NOT FOR HUMAN CONSUMPTION 

Tesofensine is a centrally acting small-molecule drug that inhibits the reuptake of serotonin (5-HT), noradrenaline (NE), and dopamine (DA). It was originally developed for neurodegenerative diseases (notably Parkinson’s and Alzheimer’s disease), but its most striking clinical signal emerged in obesity, where it produced exceptional weight lossdriven primarily by appetite suppression.

Regulatory status:
Tesofensine is investigational. It is not approved by the FDA or EMA and has no marketing authorization in the Netherlands or EU.

2) Pharmacological class and rationale

Tesofensine belongs to a rare class of balanced triple monoamine reuptake inhibitors, distinguishing it from:

• SSRIs (serotonin only),

• SNRIs (serotonin + noradrenaline),

• bupropion-like agents (dopamine + noradrenaline).

By simultaneously enhancing serotonergic satiety signaling, noradrenergic energy-expenditure signaling, and dopaminergic reward modulation, tesofensine acts on multiple, redundant appetite-control circuits in the hypothalamus and mesolimbic system.

This multi-pathway engagement explains both:

• its high efficacy, and

• its narrow therapeutic window.

3) Molecular mechanism of action

3.1 Transporter-level pharmacodynamics

Tesofensine inhibits:

• SERT → ↑ synaptic serotonin (satiety, impulse control),

• NET → ↑ noradrenaline (energy expenditure, alertness),

• DAT → ↑ dopamine (reward signaling, food motivation reduction).

Unlike stimulant anorectics, tesofensine does not act as a releasing agent; it blocks reuptake, leading to tonic elevationof monoamines.

3.2 Central appetite circuitry effects

The net result is sustained appetite suppression without acute stimulant euphoria, although sympathomimetic effects can still occur.

4) Clinical efficacy

4.1 Obesity: Phase 2 randomized trials

In placebo-controlled Phase 2 trials in adults with obesity, tesofensine produced:

• ~10–13% mean body-weight loss at 24 weeks (0.5–1.0 mg/day),

• A dose-dependent effect, with higher doses producing greater loss,

• Weight loss substantially exceeding placebo and comparable to or greater than many first-generation anti-obesity drugs.

Importantly, weight loss was driven mainly by reduced caloric intake, not malabsorption or illness-related anorexia.

4.2 Metabolic effects

Secondary outcomes demonstrated:

• ↓ waist circumference,

• ↓ triglycerides,

• modest improvements in insulin sensitivity,

• reductions in cardiometabolic risk markers proportional to weight loss.

4.3 Neurodegenerative disease programs (historical)

Earlier trials in Parkinson’s and Alzheimer’s disease showed:

• limited efficacy for primary neurological endpoints,

• but consistent weight loss as a side effect—redirecting development toward obesity.

5) Pharmacokinetics

• Route: oral

• Half-life: long (≈ 9 days), leading to gradual accumulation

• Steady state: achieved slowly over several weeks

• Metabolism: hepatic (CYP involvement suspected but not fully characterized)

The long half-life:

• contributes to durable appetite suppression, but

• complicates dose titration and adverse-event management.

6) Safety and tolerability

6.1 Common adverse effects (dose-related)

• Dry mouth

• Insomnia

• Nausea

• Constipation

• Headache

These reflect central monoaminergic activation.

6.2 Cardiovascular and autonomic effects

• ↑ heart rate (clinically meaningful in some participants),

• ↑ blood pressure (especially at higher doses),

• Mild sympathomimetic profile.

These findings were a major limiting factor in further development, particularly after historical safety failures of centrally acting weight-loss drugs.

6.3 Neuropsychiatric considerations

Because tesofensine affects dopamine and serotonin:

• Anxiety, agitation, or mood changes are theoretically possible,

• Abuse potential appears low, but careful monitoring is required.

7) Why tesofensine was not approved

Despite strong efficacy, tesofensine faced multiple challenges:

1. Cardiovascular safety bar
   Post-sibutramine, regulators require stringent CV outcome safety. Tesofensine’s HR/BP effects raised concern.

2. Long half-life risk
   Adverse effects cannot be rapidly reversed.

3. Emergence of incretin therapies
   GLP-1 and dual/triple incretin agonists offer high efficacy with more favorable CV profiles.

As a result, tesofensine stalled at Phase 2 and never advanced to pivotal trials.

8) Comparison with modern obesity pharmacotherapy

9) Regulatory and legal context (EU / Netherlands)

• Tesofensine is classified as an unapproved medicinal product.

• Illegal to sell to consumers or market for weight loss in the Netherlands.

• Only lawful use is licensed research within approved institutions.

10) Scientific legacy and future relevance

Tesofensine remains scientifically important because it demonstrates that:

• Central appetite control alone can produce dramatic weight loss, and

• Multi-pathway CNS engagement is highly effective but hard to regulate safely.

Its legacy directly informed:

• the shift away from monoaminergic anorectics, and

• the preference for peripherally initiated, centrally integrated signals (incretins).